New combo therapy aims to keep lung cancer from returning after surgery

NCT ID NCT06624059

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor was completely removed. The goal is to see if this approach can help control the disease without causing too many side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

Perugia, Umbria, 06156, Italy
Beijing Cancer Hospital

Beijing, 100142, China
Guangdong General Hospital

Guangzhou, 510000, China
Instituto do Cancer do Estado de Sao Paulo - ICESP

São Paulo, São Paulo, 01246-000, Brazil
Jinhua municipal central hospital

Jinhua, China
RedSalud Vitacura

Santiago, Chile
Royal North Shore Hospital

St Leonards, New South Wales, 2065, Australia
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
The third people's hospital of Chengdu

Chengdu, China
Yunnan Cancer Hospital

Kunming, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.